Period:
Draw Mode:
| Volume | 2,564 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PaxMedica Inc | PXMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.76 | 05:02:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.76 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 22 | 2,564 | - | 1.36 - 10.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:45:10 | 20 | $ 1.88 | USD |
PaxMedica Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 21.21M | 12.05M | 4.74M | $ - | $ - | - | 20.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 13.60% |
PaxMedica News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PXMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.35 | 2.85 | 1.74 | 2.51 | 3,961,441 | -0.59 | -25.11% |
| 1 Month | 2.10 | 2.85 | 1.42 | 2.28 | 2,067,024 | -0.34 | -16.19% |
| 3 Months | 1.85 | 4.07 | 1.42 | 2.59 | 1,284,743 | -0.09 | -4.86% |
| 6 Months | 2.26 | 4.07 | 1.36 | 2.46 | 1,207,643 | -0.50 | -22.12% |
| 1 Year | 6.50 | 10.48 | 1.36 | 3.55 | 2,096,691 | -4.74 | -72.92% |
| 3 Years | 6.50 | 10.48 | 1.36 | 3.55 | 2,096,691 | -4.74 | -72.92% |
| 5 Years | 6.50 | 10.48 | 1.36 | 3.55 | 2,096,691 | -4.74 | -72.92% |
PaxMedica Description
| PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes. |